A Clinical Study in Angelman Syndrome

This is a first in human study of an investigational antisense oligonucleotide (ASO) called “GTX-102” being evaluated in individuals with Angelman syndrome (AS). The clinical research study is sponsored by GeneTx Biotherapeutics, LLC.

What is the GTX-102-001 Study?